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ABSTRACT
Introduction. Stroke remains one of the main causes of death and the most common cause of long-term disability in adults. 
Embolic strokes of undetermined source (ESUS) amount to a significant proportion of all ischaemic strokes. Detection of atrial 
fibrillation (AF) in this group of patients would allow for a major therapeutic decision to switch from antiplatelets to oral anti-
coagulants and therefore significantly reduce the risk of recurrence.
State of the Art. Current technology allows long-term continuous ECG monitoring with different systems, including implan-
table cardiac monitors (ICM). However, in Poland lack of reimbursement does not allow their use in everyday clinical practice.
Clinical Implications. This is a statement by a Working Group conceived by the Polish National Consultants in Cardiology and 
Neurology addressing the use of ICM in patients after ischaemic embolic strokes of undetermined source. The aim was to deve-
lop reasonable and comprehensive guidance on how to select and manage candidates for ICM in order to obtain the maximum 
benefit for Polish public health.
Future Directions. This expert opinion is not intended as a guideline but it provides advice as to how to optimise the potential 
use of ICM in patients after ESUS in the Polish setting. 
Key words: acute ischaemic stroke, embolic stroke of undetermined source, atrial fibrillation, ECG monitoring 
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Therapeutic problem
Despite continuous progress in prevention and treatment 
observed over recent decades, stroke remains one of the main 
causes of death, and the most common cause of long-term 
disability, in adults in developed countries [1, 2].
In about 80% of cases stroke is ischaemic [2]. According 
to the map of health needs related to hospital treatment in 
Poland developed by the Ministry of Health, ischaemic stroke 
was the main cause of 64,400 hospital stays in Polish stroke 
units in 2016 [3]. Only about 9% of patients with the principal 
diagnosis of acute ischaemic stroke were treated in non-stroke 
departments [3]. 
The mortality rate in Polish patients after ischaemic stroke 
was 14.5% within 30 days, 21.5% within 90 days, and reached 
30.2% at 12 months [3].
In terms of aetiology, stroke is a heterogeneous condition. 
Therefore, in order to implement optimal secondary preven-
tion, it is necessary to individually identify its most probable 
cause in each patient. According to the generally applicable 
TOAST (Trial of Org 10172 in Acute Stroke Treatment) clas-
sification, the main causes of ischaemic stroke may be [4]:
 — Large artery atherosclerosis (about 25% of ischaemic 
strokes worldwide [5], and 18% in Poland [6]; 5-year 
recurrence 23%, 5-year risk of death 31% [7]). Diagnosed 
if there is ≥ 50% stenosis or occlusion of a large artery or 
its branches supplying the infarct area with no evidence 
of a cardiac source of embolism. 
 — Cardioembolism (about 20% of ischaemic strokes world-
wide [5], and 28% in Poland [6]; 5-year recurrence 25%, 
5-year risk of death 65% [7]). Diagnosed if there is at 
least one potential source of embolic material (e.g. atrial 
fibrillation, prosthetic cardiac valve, left ventricular or 
atrial thrombus, sick sinus syndrome, recent myocardial 
infarction, dilated cardiomyopathy, akinetic left ventricu-
lar segment, atrial myxoma, infective endocarditis) with 
no advanced atherosclerosis of the supplying arteries.
 — Small vessel disease (about 25% of ischaemic strokes 
worldwide [5], and 12% in Poland [6]; 5-year recurrence 
20%, 5-year risk of death about 20% [7]). Diagnosed if 
there is no clinical evidence of cerebral cortical dysfun-
ction and no evident infarct focus or a relevant brain stem 
lesion or a relevant subcortical lesion measures < 1.5 cm 
(so called lacunar lesion).
 — Other determined causes (about 5% of ischaemic strokes 
worldwide [5], about 4% in Poland). Most frequently diag-
nosed in the presence of nonatherosclerotic vasculopathies 
(e.g. dissection, fibrous dysplasia, vasculitis, moyamoya 
disease) or hypercoagulable states. 
 — No clear cause or more than one probable cause (about 
25% of ischaemic strokes worldwide [5], and up to 39% of 
ischaemic strokes in Poland [6]; 5-year recurrence 23%, 
5-year risk of death 25% [7]).
Identification of a cardioembolism is of primary impor-
tance for secondary prevention. Randomised studies have not 
revealed any clear benefits of using anti-platelet agents in this 
group, which are an implicit standard of treatment of each 
ischaemic stroke in the acute phase [8]. However, long term 
treatment with vitamin K antagonists is known to reduce the 
relative risk of another ischaemic stroke by 64% (NNT 12 in 
1 year) [8]. A similar or even higher efficacy in preventing 
stroke compared to warfarin, together with a superior safety 
profile, has been shown for novel oral anticoagulants (NOAC) 
[9, 10]. Moreover, a subsequent ischaemic stroke which occurs 
despite treatment with an oral anticoagulant is milder and has 
more favourable outcome [11]. 
Therefore, cardiological diagnostic workup, especially 
screening for cardiac arrhythmias, is one of the key elements 
of a hospital stay in the stroke unit [12]. A positive history of 
atrial fibrillation or its identification after ischaemic stroke is 
a clear indication for implementation of oral anticoagulation, 
preferably with the use of a NOAC [13].
Research data suggests that a major proportion of strokes 
of unknown aetiology, so called ‘cryptogenic’ strokes, have 
in fact an embolic origin [5]. For this reason, in 2014, a new 
subtype of cryptogenic stroke was introduced: embolic strokes 
of undetermined source (ESUS) [5]. The diagnosis of ESUS 
requires combination of all following criteria:
 — Non-lacunar ischaemic lesion responsible for the symp-
toms detected by computed tomography (CT) or magnetic 
resonance imaging (MRI) 
 — Absence of extracranial or intracranial atherosclerosis 
causing ≥ 50% luminal stenosis in arteries supplying the 
area of ischaemia (ultrasound, angio-CT or angio-MRI)
 — No major risk cardioembolic source of embolism (12-lead 
ECG, at least 24-hour Holter ECG monitoring and trans-
thoracic echocardiography)
 — No other specific cause of stroke identified 
It is estimated that 9–25% of patients with acute ischaemic 
stroke meet the criteria of ESUS [6, 14]. Compared to the other 
types of ischaemic stroke, patients with ESUS are younger, have 
milder neurological deficits, and a better chance of remaining 
independent in everyday activities [6, 14]. Therefore, in this 
group of patients optimal and intense secondary prevention 
is especially justified. 
The results of a prospective analysis of patients hospitalised 
due to acute stroke at the Institute of Psychiatry and Neuro-
logy between 2001 and 2015 show that the real proportion of 
ESUS in Poland is probably between 10% and 20% of all acute 
ischaemic strokes [6]. 
With regard to recurrence (3–6% within one year) and 
the potential therapeutic benefit of safe anticoagulation 
with NOAC, two randomised clinical trials were conducted 
to evaluate the safety and efficacy of long term treatment 
with rivaroxaban (NAVIGATE ESUS, terminated premat-
urely in 2017, N = 7,213) or dabigatran (RE-SPECT ESUS, 
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completed in 2018, N = 5,390) compared to standard dose 
aspirin [14]. Unfortunately, neither of the studies showed 
NOAC superiority in preventing strokes [15, 16] (World 
Stroke Conference 2018).  Moreover, the use of rivaroxa-
ban was associated with an increased risk of haemorrhagic 
complications [16].
As a consequence, it must be recognised that the current 
concept of ESUS has proved to be clinically impractical. Post 
hoc analyses of the abovementioned trials are likely to provide 
information as to which ESUS subpopulations might poten-
tially benefit from oral anticoagulation, based on additional 
demographic, clinical, imaging and electrophysiological cri-
teria. Nevertheless, the hypotheses generated in this way will 
have to be verified in further randomised trials. Considering 
the duration of such potential trials, new solutions may appear 
no sooner than in a few years. 
Therefore, it is reasonable to subject patients currently 
classified as having ESUS based on standard diagnostic criteria 
to further diagnostic workup. Due to the potential therapeutic 
implications, targeting confirmation of a suspected cardioem-
bolism seems to be of particular importance. This will allow 
the identification of patients with a potentially higher risk of 
recurrence than the average for the whole ESUS group, and 
subsequently reduce this risk by the introduction of an oral 
anticoagulant. 
It is desirable that ECG monitoring initiated shortly after 
ESUS be prolonged, especially in the subpopulation with addi-
tional signs of atrial disease [17–22]. Supplementary diagnostic 
procedures should be initiated as soon as possible following 
the occurrence of stroke, in order to maximise the benefits of 
potentially indicated anticoagulation. A delayed diagnosis of 
atrial fibrillation after the first ischaemic stroke is related to 
a 1.5-fold higher risk of recurrence [23]. It also needs to be 
emphasised that the curves of survival free of another stroke 
diverge already in the first year of follow-up, later becoming 
almost parallel [23]. 
Standard procedures in the acute phase of 
ischaemic stroke
Acute stroke is a life-threatening condition, and as such 
requires urgent admission to a stroke unit. The diagnosis of 
stroke is based on symptoms and clinical signs with the sup-
port of brain imaging. In Poland, the hospital stay of an acute 
stroke patient lasts in most cases eight days or longer. This time 
is fully sufficient to conduct the standard diagnostic process 
recommended by guidelines, including the guidelines from 
the Section of Vascular Diseases at the Polish Neurological 
Society [12, 24, 25]:
 — Brain imaging: CT (usually), CT and MRI (sometimes), 
or only MRI (rarely); performed at least once on admis-
sion to hospital; allows a determination to be made as to 
whether the stroke is ischaemic or haemorrhagic; it can 
reveal an acute lesion, silent brain infarcts, and signs of 
small vessel disease 
 — Vascular imaging: carotid ultrasound (always), transcra-
nial Doppler (usually), CT angiography or MRI angio-
graphy (sometimes additionally); performed to assess 
atherosclerosis and confirm or exclude other less common 
vascular pathologies
 — Screening for cardiac arrhythmias: resting ECG (at least 
once), monitoring of heart rate with a cardiomonitor for 
at least 24 hours (almost always), 24-hour Holter monito-
ring (usually); may detect previously undiagnosed atrial 
fibrillation
 — Echocardiography: transthoracic echocardiography (usu-
ally), transoesophageal echocardiography (as a supple-
mentary examination is some cases); may detect source 
of cardiac embolism
Reperfusion therapy is the gold standard of treatment in all 
eligible cases. Intravenous thrombolysis is available at all Polish 
stroke units and is fully reimbursed. Currently, such treatment 
is used in about 13% of patients. Mechanical thrombectomy as 
a therapy supporting thrombolytic treatment, or as the therapy 
of choice in patients not eligible to thrombolysis, is indicated 
for strokes caused by occlusion or critical stenosis. In Poland 
it is not reimbursed and is therefore used in less than 1% of 
patients. A pilot project launched by the Ministry of Health 
in January 2019 should enable reasonable nationwide access 
to thrombectomy within the next few years. 
All acute patients who are not eligible for reperfusion 
therapy should receive anti-platelet therapy (usually 150-
300 mg of aspirin, or sometimes a combination of aspirin and 
clopidogrel). Aspirin is also initiated 24 hours after reperfusion 
therapy [12, 24, 25].
After the acute phase, long-term treatment with aspirin 
75–150 mg is maintained unless the stroke has been considered 
to be cardioembolic. In such cases, aspirin should be replaced 
with an oral anticoagulant as soon as it is safe for the patient 
[12, 24–26].
Atrial fibrillation and ischaemic stroke
According to the guidelines, atrial fibrillation (AF) is diag-
nosed on an electrocardiogram showing completely irregular 
R-R intervals with the absence of marked P waves, lasting at 
least 30 s [13, 27]. AF is the most common arrhythmia in the 
population. Its prevalence in the general population is about 
1–2% of patients on average. In selected risk groups (e.g. old 
age, ESUS, numerous general and cardiological diseases), this 
proportion is much higher [13, 27]. 
AF aetiology is believed to be multifactorial. It entails 
genetic conditioning, as well as comorbidities and lifestyle [27]. 
AF may become manifest with general weakness, the 
sensation of skipping beats, reduced exercise tolerance, chest 
discomfort, sleeping disorders or anxiety. Basic AF therapy 
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are not reimbursed, and the National Health Fund does not 
account for the number of days of Holter ECG monitoring, nor 
does it provide separate financing of external or implantable 
arrhythmia recorders. 
Considering these limitations, and the uncertainty about 
long-term benefit, it is suggested that only patients with the 
highest risk of AF occurrence should be referred for such 
diagnostic workup [18]. Observational studies consistently 
point to older age as the main risk factor of the occurrence/
recognition of AF after cryptogenic stroke [20]. 
Currently there are three initially validated scoring systems 
used to stratify the risk of occurrence/recognition of AF in 
patients scheduled for long-term ECG monitoring after ESUS 
that are worth mentioning. These are:  MrWALLETS (from -2 to 
5 points) [31], HAVOC (from 0 to 14 points) [32], and Brown 
ESUS-AF score (from 0 to 4 points) [33]. According to a group 
of experts from the German Cardiac Society and the German 
Stroke Society there are several predictors of AF in patients after 
ischaemic stroke, including age ≥ 75 years, left atrial diameter 
> 45 mm, detection of supraventricular arrhythmias and incre-
ased serum BNP or NT-proBNP level [18]. In contrast, age 
< 60 years, left atrial diameter < 40 mm, low number of supra-
ventricular arrhythmias and low serum BNP or NT-proBNP 
level suggest a low probability of detecting AF [18].
This set of variables overlaps with the Brown ESUS-AF 
score (age 65–74 years = 1 point, age ≥ 75 years = 2 points, 
moderate or severe left atrial enlargement = 2 points). The 
Brown ESUS-AF score has been developed based on the 
analysis of 296 ESUS patients subjected to prolonged ECG 
monitoring (initial 30-day external monitoring followed by 
optional ICM implantation). Atrial fibrillation was detected 
in 21% of patients in a subgroup scoring 2 points (sensitivity 
63%, specificity 71%), in 22% of patients scoring 3 points, and 
in 56% of patients scoring 4 points [33].
In our opinion, ICM implantation is especially justified 
in two groups of patients after an ESUS that did not result 
in a permanent loss of independence in performing daily 
activities:
 — Age 65–74 years with left atrial enlargement ≥ 45 mm
 — Age ≥ 75 years with left atrial enlargement > 40 mm 
It may be assumed that after such selection ICM moni-
toring should result in the detection of AF in about 30% of 
patients (similarly to the group with ≥ 2 points in the Brown 
ESUS-AF score). 
Clinical aspects of the use of ICM 
Modern cardiac implantable electronic devices (CIED: 
cardiac pacemakers, cardioverter defibrillators, resynchro-
nisation therapy systems), if they enable direct recording of 
atrial electrical activity, are the best model for identifying 
supraventricular tachyarrhythmias, since they can do it 
continuously, 24 hours a day. The system should allow for an 
involves a strategy of rhythm control or ventricular rate control 
[13]. AF may result in serious complications leading to death or 
significant disability: cardiac insufficiency, ischaemic stroke or 
peripheral embolism [13]. The basis of primary and secondary 
prevention of stroke is oral anticoagulant therapy (OAT). Each 
patient should undergo risk stratification regarding vascular 
events with the use of a CHA2DS2-VASc scale, and if a score 
of 2 or higher is achieved – oral anticoagulation should be 
introduced [13]. It must be remembered that a history of 
ischaemic stroke adds 2 points to the total CHA2DS2-VASc 
score [13]. This means in practice that oral anticoagulation is 
indicated for every patient with a history of atrial fibrillation 
and ischaemic stroke, regardless of the time of its detection. 
ECG monitoring
Due to the potentially serious embolic consequences of AF 
and the possibility of their effective prevention, all scientific 
societies and expert groups find it justified to screen for AF 
patients with a high risk of stroke [13, 27]. ESUS patients also 
belong in the group of high risk of both AF and recurrent 
stroke. Therefore prolonged ECG monitoring after ESUS is 
recommended both during the stroke unit stay and in the 
outpatient setting. 
Monitoring may be non-invasive (e.g. prolonged Holter 
monitoring, external arrhythmia recorders, electronic devices) 
or invasive, in the form of an implantable cardiac monitor 
(ICM) [27]. 
Clinical trials have shown that the longer the monitoring, 
the greater the chance of detecting AF. In CRYSTAL-AF, the 
use of ICM in patients after cryptogenic stroke resulted in 
diagnosing AF in an additional 7.5% of patients (8.9% vs 1.4%) 
within six months, in an additional 10.4% (12.4% vs 2.0%) 
within 12 months, and in an additional 27.0% (30.0% vs 3.0%) 
within three full years of follow-up [28, 29]. In another clinical 
trial, during a one year follow-up, ICM implantation yielded 
an additional 15.3% (17% vs 1.7%) AF diagnoses compared 
to 7-day Holter monitoring [30]. Unfortunately, there are no 
randomised studies confirming the clinical benefits of anti-
coagulation therapy in AF diagnosis made with the use of 
ICM. However, there are no reasons to believe that they will 
significantly differ from the benefits experienced by patients 
with AF diagnosed with the use of standard ECG monitoring. 
In current clinical practice, prolonged ECG monitoring 
after a stroke is rare, and qualification for such monitoring is 
highly individualised [19]. Such practice results from limited 
financial and human resources and definitely brings no benefit 
on the level of public health [19]. On the other hand, the high 
direct cost of prolonged ECG monitoring require the proper 
selection of patients to maximise the proportion of screenings 
yielding positive results.
Currently, Polish patients have very limited access to long-
-term ECG monitoring. ICM implantation and follow-up visits 
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intracardiac electrogram (IEGM). Based only on the criterion 
of atrial electrical activity, episodes with a rate exceeding 
160–170 beats/min are usually considered to be atrial high 
rate episodes (AHRE). Such episodes may include various 
supraventricular tachycardias, not only episodes of atrial 
flutter/fibrillation. Therefore, confirmation of the latter is only 
possible via a careful analysis of IEGM. It must be emphasised 
that CIEDs are implanted based on a set of well-described 
indications, and a diagnosis of AHRE is just a side effect of 
the primary function of the device. 
The 2016 guidelines of the European Society of Cardio-
logy on atrial fibrillation recommend (as class I indications) 
a regular CIED memory interrogation in order to identify 
AHRE [13]. Patients with diagnosed AHRE should undergo 
further ECG monitoring in order to document potential AF 
episodes before the onset of oral anticoagulant therapy, while 
IEGM recording is enough to document the arrhythmia. The 
same recommendations for patients after stroke suggest the 
consideration of additional (more than 72 hours) long-term 
ECG monitoring with the use of non-invasive ECG recorders 
or ICM in order to document AF. Implantable cardiac monitors 
are small devices [mm] 45–88.4 x 7–15.2 x 3–6.2, depending 
on the manufacturer and model. The recorders are implanted 
subcutaneously in the parasternal region, in the 4th intercostal 
space. The battery allows operation of the device for 2–4 years. 
The implantation procedure is minimally invasive and perfor-
med under local anaesthesia, in the setting of an operating 
room or treatment room, and is characterised by 100% efficacy. 
The device is oriented to achieve the highest possible amplitude 
of ventricular complexes, usually at a 45 degree angle to the 
sternal long axis, along the sternum or in any other position 
between the above two. 
Another element of the system is the possibility of telemo-
nitoring. A special modem enables automatic transmission of 
arrhythmic episodes to a dedicated server. The episodes are 
available for a physician taking care of the patient within 24 ho-
urs of their occurrence. ICMs record only ventricular electrical 
activity (QRS complexes), so episodes of atrial fibrillation may 
be suspected only thanks to special algorithms which assess 
irregularities of R-R intervals on the basis of the analysis of 
Lorentz plots. Detection of atrial fibrillation is possible when 
the arrhythmia lasts for at least two minutes. The algorithms 
detecting atrial fibrillation based on the analysis of changes 
in R-R intervals are also available in some models of single 
chamber cardioverter defibrillators. Basic technical data of 
particular ICMs are presented in Table 1.
Device interrogation (including device memory) is usually 
conducted every 3–12 months in the device control clinic or 
by means of remote control (based on the telemonitoring 
technology) with the same time intervals as controls in the 
clinic. In the latter case, it is recommended that once a year the 
interrogation is performed during a visit to the clinic. As pre-
viously mentioned, the remote control of devices enables not 
only automatic reporting at pre-programmed time intervals, 
but also immediate transmission of information about a sig-
nificant clinical event (e.g. episode of atrial fibrillation) within 
24 hours of its occurrence.
Asymptomatic episodes of atrial fibrillation are much more 
frequent than symptomatic ones. In a study by Orlow et al., 
which included 427 patients with an implanted pacemaker in 
accordance with applicable indications, the risk of an atrial 
high rate episode after two years of follow-up was 53.8% and 
88.6% in a subgroup without and with a history of supra-
ventricular tachyarrhythmias, respectively [34]. Moreover, 
the episodes were asymptomatic in these groups in 94.7% 
and 75.3% of cases, respectively. The symptoms reported 
by patients were not consistent with arrhythmia episodes in 
most of the enrolled patients. Importantly, as much as 93% of 
AHREs were, in fact, supraventricular tachyarrhythmias and 
not AFs. In another study involving patients with an implanted 
CIED, it was found that as much as 95% of AF episodes are 
asymptomatic [35]. The percentage of correct AF diagnoses 
based on the analysis of AHRE in the ICM memory increases 
with the episode duration: starting from 83% for episodes 
> 6 minutes up to 97% for episodes > 6 hours [34]. False 
positive AHRE diagnoses are usually caused by episodes 
of: repetitive non-reentrant ventriculo-atrial synchrony 
(RNRVAS) – 80.4%, R-wave oversensing on the atrial lead 
– 7.5%, interference – 6.9%, and other factors – 5.2%.
A subanalysis of the CRYSTAL-AF trial, which included 
patients after ischaemic stroke with ICM, compared the 
sensitivity of detecting AF episodes between ICM and other 
ECG recording methods [36]. Compared to ICM, one 24-hour 
Holter examination showed a sensitivity of 1.3%, and a con-
tinuous 30-day examination 22.8%. With a 24-hour Holter 
examination repeated every three months this figure was 3.1%, 
and with a 7-day examination it was 20.8%. It is apparent that 
compared to an AF diagnosis based on implantable episode 
recorders, all other analysed methods of ECG registration 
allow detection of only one in every four AF episodes.
The latest algorithms of atrial fibrillation implemented in 
ICMs are characterised by over 99% sensitivity and a positive 
predictive value of 95% [37].
Optimal patient pathway  
for ICM implantation 
To ensure early detection and quick therapeutic decision 
after the occurrence of clinically significant arrhythmia the 
process of qualification, implantation and outpatient follow-up 
needs to be standardised.
a) Tasks of the stroke centre
•	 Identification of an ESUS patient eligible for ICM 
implantation
•	 Brief explanation of the whole procedure and obtaining 
patient’s initial consent to a possible ICM implantation
•	 Initiation of the process of final qualification for ICM 
implantation at the collaborating cardiological centre
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b) Tasks of the cardiological centre
•	 Verification of indications for ICM implantation based 
on patient’s medical records and discussing alterna-
tive methods of long-term ECG monitoring that are 
currently available 
•	 ICM implantation 
 ■ ICM implantation in the CIED operating room; 
perioperative antibiotic prophylaxis in accordance 
with local standards is required; the procedure 
should be performed by a cardiologist experienced 
in CIED implantations 
 ■ ICM interrogation before discharge 
•	 Schedule of follow-up visits 
 ■ Permanent remote monitoring in accordance 
with the standard of a given centre, but allowing 
everyday assessment of ICM report. If remote mo-
nitoring is not possible, additional visits should be 
scheduled to ensure that the device is interrogated 
every three months.
 ■ Follow-up visit 3 months after implantation: 
assessment of the implantation site and ICM 
function 
 ■ Follow-up visits every 12 months 
 ■ Emergency visit in the case of recorded arrhythmia 
requiring a therapeutic decision 
Observational studies show that the real-life diagnostic 
workup in Polish stroke units may not be sufficient to clearly 
determine if a given cryptogenic stroke may be classified as 
ESUS [6]. Therefore, if the patient has an opportunity of cost-
-free long-term ECG monitoring, it is especially important 
to start by making a diagnosis of ESUS as described in the 
previous section. It should also be considered to introduce an 
additional procedure of 48–72-hour ECG Holter monitoring 
or to equip stroke units with telemetric systems capable of 
automated detection of arrhythmias and adding it to the NHF 
list of procedures for stroke. 
Follow-up visits should be performed by a cardiologist 
capable of addressing different cardiac conditions. It is impor-
tant to provide the possibility of a telemetric rhythm control 
to ensure quick diagnosis of arrhythmias and immediate 
implementation of adequate treatment. ICM telemonitoring 
was an integral part of the diagnostic strategy used in clinical 
trials and therefore influenced the outcomes [28–30]. 
In our opinion, it is reasonable to maintain ICM and con-
tinue follow-up visits until battery depletion even in patients 
with AF detected by the device. This strategy is justified by 
the risk coincidence of clinically significant arrhythmias other 
than AF, and by the possibility of monitoring the AF treatment 
efficacy or diagnosing syncopes. The real costs of outpatient 
ICM visits may be considered similar to pacemaker visits, 
since they require a detailed overview and verification of all 
automatically detected and recorded episodes. The annual 
cost of telemedical follow-up is estimated to equal the cost of 
four pacemaker visits. 
Recommended conditions of arrhythmia 
monitoring with ICM following ESUS 
a) Neurological centres
•	 Stroke unit which admits at least 200 patients with 
ischaemic stroke a year
•	 Equipment and human resources allowing full stan-
dard diagnostic workup necessary to diagnose ESUS 
in each patient with cryptogenic ischaemic stroke
•	 Ability to provide follow-up at the hospital outpatient 
neurological clinic
b) Cardiological centres 
•	 Ability to implant ICM within 4 weeks from the first 
information received from the cooperating stroke 
centre about a patient meeting neurological criteria 
of qualification
•	 Resources ensuring comprehensive care of AF patient, 
i.e. a team experienced in CIED procedures and 
electrophysiology (EP), CIED/EP operating theatre, 
on-site transthoracic and transoesophageal echocar-
diography, on-site access to prolonged ECG exami-
nation (7-day Holter, external arrhythmia recorders), 
CIED outpatient clinic, on-site general cardiological 
outpatient clinic
•	 Experience in remote monitoring of CIED 
•	 Possibility of delivering a cardiological consultation 
on a 24-hour basis 
Table 1. Basic technical data of selected implantable arrhythmic episode recorders
Manufacturer Abbott Biotronik Medtronic
Model Confirm Rx™1DM3500 Biomonitor 2 Reveal LINQ  
LNQ1
Dimensions (mm): length x width x thickness 49 x 9 x 3 88.4 x 15.2 x 6.2 45 x 7 x 4
Volume (cm3) 1.4 5 1.2
ECG storage capacity (min) 60 66 59
Diagnosed episodes Asystole, Brady, Tachy, AF Asystole, Brady, AF, HVR, SRD Asystole, Brady, Tachy, AT, AF
Mean time of operation (years) 2 4 3 
AF – atrial fibrillation; AT – atrial tachycardia; HVR – high ventricular rate; SRD – sudden rate drop
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Health needs at the national level 
In order to estimate the health needs in the area of ICM 
implantation after ESUS, an additional analysis was conducted 
based on the material used in the study of Bembenek et al., 
making the following assumptions [6].
 — The results presented in the publication of Bembenek 
et al. may be extrapolated to the general Polish population
 — Inclusion criteria are the first-ever ischaemic stroke, age 
≥ 65 years, and left atrial enlargement
 — Annual number of patients admitted to Polish stroke units 
for acute ischaemic stroke is 64,400
 — At discharge from the stroke unit the patient is assessed as 
independent in daily activities (0–2 points on the modified 
Rankin Scale) 
In the basic variant (i.e. assuming that the proportion 
of ESUS patients will be equal to the proportion of patients 
with a certain ESUS diagnosis), the annual number of patients 
eligible for intense prolonged ECG monitoring may amount 
to 800. In the maximum variant (i.e. including patients not 
classified as certain ESUS due to not having echocardiograp-
hy), the annual number of cases may rise to 1,625. 
Additionally, it must be emphasised that the data stored 
in the registry did not allow determination of the degree of 
left atrial enlargement. This means that the actual population 
size is probably less numerous. Moreover, not every patient 
will be willing to undergo a procedure that requires repeated 
visits to a specialised cardiological centre. 
Conclusion
Adequate cardiological workup is one of the main factors 
determining the type of pharmacotherapy used in the secon-
dary prevention of ischaemic stroke. In a large proportion of 
patients, standard diagnostics do not allow stroke aetiology to 
be determined. Therefore, there is a need for closer cooperation 
between stroke centres and cardiological centres and a need 
for systemic solutions that would facilitate such cooperation.
Research data indicates, that early initiation of prolonged 
ECG monitoring in a properly selected group of patients 
after embolic stroke of undetermined source could provide 
the chance of detecting atrial fibrillation, consequently re-
ducing the risk of recurrence by timely introduction of oral 
anticoagulation. 
Current technology allows long-term continuous ECG 
monitoring with the use of ICM. Due to high patient cost and 
the lack of dedicated financing from the NHF, this medical 
technology is not available to a Polish stroke patient. Neverthe-
less, considering the health benefits in the context of the whole 
population, efforts should be made to implement long term 
ECG monitoring after ESUS in reasonably selected patients.
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